RxDoctor Payments Data

Jose Ricardo Po, MD

Cardiovascular Disease · Three Rivers, MINPI 1073743118

Payments from drug & device makers

$2,239in general payments, 2019–2025

Across 39 payments — averaging $57.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$604
  • Boston Scientific$526
  • E.r. Squibb & Sons, L.L.C.$398
  • Heartflow, Inc.$243
  • Novartis$120
  • Johnson & Johnson$87
  • plus $261 from 8 others

What the payments were for

  • Travel & lodging$54024%
  • Food & beverage$1,69976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,239 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$124,086
Medicare patients
1,049
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$362,487
XareltoRivaroxaban166$194,295
EntrestoSacubitril/Valsartan97$127,770
JardianceEmpagliflozin54$66,082
Repatha SureclickEvolocumab11$17,945
Praluent PenAlirocumab24$17,768
MultaqDronedarone Hcl22$17,044
Metoprolol Succinate615$10,538
Ranolazine ErRanolazine23$5,474
Atorvastatin Calcium454$5,471
Carvedilol219$2,803
ClopidogrelClopidogrel Bisulfate237$2,743
Losartan Potassium206$2,524
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$2,355
Bumetanide57$2,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$362,487327 claims
Johnson & JohnsonXarelto$87$194,295166 claims
NovartisEntresto$120$127,77097 claims
Boehringer IngelheimJardiance$13$66,08254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Three Rivers

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →